Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07564414 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Name: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — clinical trial record (NCT07564414)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2026-05-21

View on ClinicalTrials.gov ↗

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Amendment history 1 change detected by DataLookout

2026-05-30

Recruitment opened

Trial Details

NCT Number	NCT07564414
Lead Sponsor	Novo Nordisk A/S
Conditions	Obesity, Type 2 Diabetes
Enrollment	2,500 participants
Start Date	2026-05-21
Primary Completion	2028-02-23 (estimated)
Study Completion	2028-04-19 (estimated)
Updated on ClinicalTrials.gov	2026-08-31